Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Headline outcomes only

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 2 · 100%

Overall survival · EGFR M+ patients with NSCLC

Afatinib showed no clear difference in overall survival compared with chemotherapy (high certainty).

1 finding from 1 review

Progression‐free survival · EGFR M+ patients with NSCLC

Afatinib leads to lower progression‐free survival compared with chemotherapy (high certainty).

1 finding from 1 review